Immunogenicity and safety of concurrent or sequential administration of live, attenuated SA 14-14-2 Japanese encephalitis vaccine (CD-JEV) and measles-mumps-rubella vaccine in infants 9–12 months of age in the Philippines: A non-inferiority Phase 4 randomized clinical trial. (11th December 2020)

• Record Type: Journal Article
• Authors: Capeding, Maria Rosario; Alberto, Edison; Feser, Jodi; Mooney, Jessica; Tang, Yuxiao; Audet, Susette A.; Beeler, Judy A.; Ellison, Damon W.; Zhang, Lei; Letson, G. William; Neuzil, Kathleen M.; Marfin, Anthony A.
• Is Part Of: Vaccine. Volume 6(2020)
• Publication Date: 2020-12-11
• DOI: 10.1016/j.jvacx.2020.100074
• Languages: English
• ISSNs: 2590-1362

Abstract

Highlights: Live, attenuated SA 14-14-2 JE vaccine is immunogenic when given with MMR vaccine. Live, attenuated SA 14-14-2 JE vaccine is safe when given with MMR vaccine. Live, attenuated SA 14-14-2 JE vaccine may be coadministered with MMR vaccine. Abstract: Introduction: Japanese encephalitis (JE) virus is the leading cause of viral encephalitis across temperate and tropical zones of Asia. The live attenuated SA 14-14-2 JE vaccine (CD-JEV) is one of three vaccines prequalified by the World Health Organization (WHO) to prevent JE. When incorporating a new vaccine into a country's Expanded Program on Immunization (EPI), it is important to show that the new vaccine can be administered concurrently with other routine pediatric vaccines without impairing the immune responses or changing the safety profiles of the co-administered vaccines. This Phase 4 open-label study evaluated the safety and immunogenicity of measles-mumps-rubella (MMR) vaccine co-administered with CD-JEV. Methods: The study randomized 628 healthy Filipino children aged between 9 and 10 months to receive MMR and CD-JEV concurrently or separately. MMR immunogenicity was measured 56 days after MMR vaccination using a measles plaque reduction neutralization test (PRNT), anti-mumps immunoglobulin G (IgG) enzyme-linked immunosorbent assay (ELISA), and anti-rubella IgG ELISA, respectively. Neutralizing antibody against JE virus was measured 28 days after CD-JEV vaccination using PRNT. Safety was assessed through solicitation of immediate reactions, adverse events (AEs) within 14 days of vaccination, unsolicited AEs occurring within 28 days, and serious adverse events (SAEs) during participation in the study. Results/Conclusions: During the study, no post-vaccinal encephalitis cases or related SAEs were reported in either group. Concurrent immunization with CD-JEV and MMR vaccines was not associated with any unusual safety signals when compared with sequential immunization. No significant differences between the regimens were seen in seropositivity or serology titer/concentration results for any of the antigens. Co-administration of CD-JEV and MMR was non-inferior to single administration of either vaccine.